Once a Takeover Candidate, Vertex Is Now Looking for Deals

Updated on
  • CEO says cystic fibrosis success justifies stand-alone company
  • Biotech firm would consider potential gene therapy, RNA deals

Vertex Pharmaceuticals Inc. has ranked high on investors’ lists of likely biotech acquisition targets. Now that the drugmaker is on the path to profit, it’s the one ready to go shopping.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.